Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 6th Annual Israel Conference
- Live video webcast with CEO, Jeffrey Eisenberg, on Tuesday, November 12th at 8:00 AM EST -
FRAMINGHAM, MA / ACCESSWIRE / November 5, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at the H.C. Wainwright 6th Annual Israel Conference on Tuesday, November 12, 2020 at 8:00 AM EST.
In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
A live video webcast of the presentation will be available on the IR Calendar page of the Investors section of the Company's website (xeneticbio.com). The video webcast replay will be made available two hours following the event and will be archived for 90 days.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Additionally, Xenetic is leveraging PolyXen®, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen® has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and receives royalty payments under this agreement.
JTC Team, LLC
SOURCE: Xenetic Biosciences, Inc.
View source version on accesswire.com:
Released November 5, 2020